Rationale and design of the Anticoagulant Therapy after Left Atrial Appendage Closure (ATLAAC) Trial

Therapy and Intervention

Single versus Dual Antiplatelet Therapy after Left Atrial Appendage Closure: a Propensity Score Matching Analysis

Heart Rhythm

Galea R, Krsnik JP, Bini T, Chalkou K, Gasys A, Brugger N, Madhkour R, Seiffge DJ, Roten L, Siontis GCM, Räber L

doi: 10.1016/j.hrthm.2024.12.007

Atrial FibrillationFurther Publications

Relative Benefit of Dual Versus Single Antiplatelet Therapy Among Patients With Atrial Fibrillation on Oral Anticoagulation According to Time After ACS and PCI: Insights From the AUGUSTUS Trial

Circ Cardiovasc Interv

Fanaroff AC, Wojdyla DM, Granger CB, Goodman SG, Aronson RS, Windecker S, Mehran R, Alexander JH, Lopes RD

doi: 10.1161/CIRCINTERVENTIONS.123.013596

Atrial FibrillationThrombosis and Stroke

Long-term outcomes after echocardiography versus fluoroscopy-guided left atrial appendage closure: Is there still a role for a simplified approach?

Catheter Cardiovasc Interv

Gilhofer TS, Schweiger V, Gehler M, Bokemeyer V, Chen M, Candreva A, Würdinger M, Di Vece D, Templin C, Niederseer D, Stähli BE, Stehli J, Gotschy A, Jakob P, Ruschitzka F, Binder R, Nietlispach F, Michel J, Kasel AM

doi: 10.1002/ccd.31126

Atrial FibrillationHeart Failure

Catheter-based ablation to improve outcomes in patients with atrial fibrillation and heart failure with preserved ejection fraction: Rationale and design of the CABA-HFPEF-DZHK27 trial

Eur J Heart Fail

Parwani AS, Kääb S, Friede T, Tilz RR, Bauersachs J, Frey N, Hindricks G, Lewalter T, Rienstra M, Rillig A, Scherr D, Steven D, Kirchhof P, Pieske B

doi: 10.1002/ejhf.3373

Atrial FibrillationHeart, Artery and Coronary Diseases

Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials

J Am Coll Cardiol

Rashedi S, Keykhaei M, Sato A, Steg PG, Piazza G, Eikelboom JW, Lopes RD, Bonaca MP, Yasuda S, Ogawa H, Shizuta S, Kimura T, Okumura Y, Andreotti F, Bertoletti L, Stone GW, Mehran R, Cohen DJ, Lip GYH, Bikdeli B

doi: 10.1016/j.jacc.2024.12.030

SPECIAL REPORT

Atrial Fibrillation

Considerations When Switching Direct Oral Anticoagulation Therapy in Patients with Non-Valvular Atrial Fibrillation

Atrial Fibrillation

Design and Rationale of a Pragmatic Randomized Clinical Trial of Early Dronedarone versus Usual Care to Change and Improve Outcomes in Persons with First-Detected Atrial Fibrillation - The CHANGE AFIB Study

Am Heart J

Pokorney SD, Nemeth H, Chiswell K, Albert C, Allyn N, Blanco R, Butler J, Calkins H, Elkind MSV, Fonarow GC, Fontaine JM, Frankel DS, Fermann GJ, Gale R, Kalscheur M, Kirchhof P, Koren A, Miller JB, Rashkin J, Russo AM, Rutan C, Steinberg B, Piccini JP

doi: 10.1016/j.ahj.2024.10.001

Thrombosis and StrokeTherapy and Intervention

Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial

Lancet

Veltkamp R, Korompoki E, Harvey KH, Harvey ER, Fießler C, Malzahn U, Rücker V, Montaner J, Caso V, Sibon I, Ringleb P, Halse O, Hügen K, Ullmann S, Schuhmann C, Todd GP, Haas K, Palà E, Debette S, Lachaize M, D'Aoust T, Enzinger C, Ropele S, Fandler-Höfler S, Haidegger M, Wang Y, Wafa HA, Cancelloni V, Mosconi MG, Lip GYH, Lane DA, Haefeli WE, Foerster KI, Wurmbach VS, Nielsen PB, Hajjar K, Müller P, Poli S, Purrucker J, Laible M, D'Anna L, Silva Y, de Torres Chacon R, Martínez-Sánchez P, Boulanger M, Norrving B, Paré G, Wachter R, Ntaios G, Wolfe CDA, Heuschmann PU, PRESTIGE-AF Consortium

doi: 10.1016/S0140-6736(25)00333-2

Myocardial Infarction

Design and Rationale of the CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine versus placebo and Spironolactone versus placebo in Patients with Myocardial Infarction